R176
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.410
- HEME_METABOLISM+0.240
- DNA_REPAIR+0.230
- NOTCH_SIGNALING+0.200
- P53_PATHWAY+0.200
- UNFOLDED_PROTEIN_RESPONSE+0.180
- WNT_BETA_CATENIN_SIGNALING+0.160
- PI3K_AKT_MTOR_SIGNALING+0.140
- OXIDATIVE_PHOSPHORYLATION+0.110
- GLYCOLYSIS+0.090
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.420
- ANGIOGENESIS-0.380
- UV_RESPONSE_DN-0.340
- SPERMATOGENESIS-0.330
- KRAS_SIGNALING_UP-0.320
- G2M_CHECKPOINT-0.310
- E2F_TARGETS-0.290
- COAGULATION-0.280
- PANCREAS_BETA_CELLS-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R165 | — | — | 0.878 |
| 2 | R32 | — | — | 0.788 |
| 3 | TCGA-94-8491-01A-11R-2326-07 | — | cohortSQ1 | 0.787 |
| 4 | TCGA-95-7948-01A-11R-2187-07 | — | cohortA1 | 0.779 |
| 5 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.772 |
| 6 | TCGA-DK-A1AG-01A-11R-A13Y-07 | — | — | 0.771 |
| 7 | SRR12475146 | — | — | 0.770 |
| 8 | SRR6013506 | — | cohortA2 | 0.761 |
| 9 | DRR168599 | — | — | 0.750 |
| 10 | MDT-AP-2588 | Med | Medulloblastoma | 0.735 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.410 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.240 | Temsirolimus | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.200 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.180 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.140 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.110 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.090 | Inavolisib | — uncovered |
| PEROXISOME | 0.060 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.030 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.020 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.010 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |